rTMS for Parkinson Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Michigan, Ann Arbor, MI
Parkinson Disease
rTMS - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for Parkinson disease is the use of drugs that provide dopamine replacement therapy (DRT). However, as the disease progresses there are prominent DRT-resistant features of Parkinson disease that are a major source of disability. These include cognitive (attention, memory) impairments and gait disorders such as freezing and falls. Repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, holds promise for the study and treatment of motor and cognitive deficits in persons with Parkinson's. To date, there are no conclusive results regarding an optimal rTMS protocol for recovery of motor and cognitive deficits in Parkinson's disease. This study is designed to promote clinical rehabilitation neuroscience research, and aims to improve rehabilitation in persons with Parkinson's with freezing of gait. This work will evaluate the use of a new accelerated, high dose, non-invasive brain stimulation method for treatment of freezing of gait in PD and will test how applying targeted accelerated stimulation to the brain improves gait disturbance due to PD.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Parkinson Disease

Study Objectives

4 Primary · 2 Secondary · Reporting Duration: Baseline; 48 hours post; 14 days post -intervention

Day 14
Percentage change in accuracy to precision force-tracking task at 48 hours and 14 days post-intervention
Baseline; 7-10 hours post-intervention
Changes in functional connectivity and BOLD signal in the basal ganglia-cerebellar-cortical network during resting state and task-based fMRI 7-10 days post-intervention
Week 1
Retention rate
Day 14
Net changes in FOG-Q scores at 48 hours and 14 days post-intervention
Percentage change in TUG test time to 48 hours and 14 days post-intervention
up to six treatment days
Participant perception of treatment acceptability

Trial Safety

Safety Progress

1 of 3

Other trials for Parkinson Disease

Side Effects for

Experiment 1: Parietal Cortex rTMS Stimulation - 4 Days
0%Migraine
0%Intolerance to stimulation
This histogram enumerates side effects from a completed 2020 Phase 1 & 2 trial (NCT03050801) in the Experiment 1: Parietal Cortex rTMS Stimulation - 4 Days ARM group. Side effects include: Migraine with 0%, Intolerance to stimulation with 0%.

Trial Design

1 Treatment Group

Open label treatment
1 of 1
Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: rTMS · No Placebo Group · N/A

Open label treatment
Device
Experimental Group · 1 Intervention: rTMS · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
rTMS
2008
Completed Phase 3
~730

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline; 48 hours post; 14 days post -intervention
Closest Location: University of Michigan · Ann Arbor, MI
Photo of university of michigan comprehensive cancer center 1Photo of university of michigan comprehensive cancer center 2Photo of university of michigan comprehensive cancer center 3
2022First Recorded Clinical Trial
17 TrialsResearching Parkinson Disease
1005 CompletedClinical Trials

Who is running the clinical trial?

University of MichiganLead Sponsor
1,597 Previous Clinical Trials
6,329,037 Total Patients Enrolled
19 Trials studying Parkinson Disease
1,458 Patients Enrolled for Parkinson Disease

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have Parkinson disease (PD) based on the recent Movement Disorder Society criteria.
You have Parkinson's disease (PD) and are >45 years old.
H&Y2-3 (early PD) subjects will be recruited.
You are a native English speaker.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.